Loading...
Clinical trials have shown statins’ benefits in patients with established coronary artery disease, but individuals with heart failure (HF) have typically been excluded from these trials. Investigators in this manufacturer-sponsored trial randomized 5011 patients (age ≥60) with symptomatic HF attributed to CAD and left ventricular systolic dysfunction (mean LV ejection fraction, 31%) to receive either rosuvastatin (10 mg/day) or placebo. Median follow-up was 33 months.
Patients in the rosuvastatin group — but not those in the placebo group — had substantially reduced LDL-cholesterol and high-sensitivity C-reactive protein levels. However, the rate of the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, and n…